The IDO1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line, featuring targeted disruption of the IDO1 gene. This polyclonal pool is generated without single-cell cloning, providing a heterogeneous mixture of loss-of-function alleles intended to ablate functional IDO1 expression. The knockout model serves as a versatile tool for dissecting IDO1-mediated immune regulation and metabolic pathways in a colon cancer context. Researchers can employ standard assays such as kynurenine production measurement by HPLC, IDO1 western blotting, and RT-qPCR to verify functional depletion of the immunosuppressive enzyme in this genetically modified population.
The host cell line, HT29, is a well-characterized adherent epithelial model originally established from a primary human colorectal adenocarcinoma. These cells retain many properties of differentiated intestinal epithelium and are widely used for studying colon cancer biology, barrier function, and tumor microenvironment interactions. Their robust growth and consistent morphology make HT29 cells suitable for co-culture experiments, signaling studies, and high-throughput compound screening. The IDO1 knockout derivative leverages this established background to enable focused investigation of immune evasion mechanisms inherent to colorectal tumors.
IDO1 (indoleamine 2,3-dioxygenase 1) functions as an immunosuppressive enzyme by catalyzing the rate-limiting step of tryptophan catabolism along the kynurenine pathway. This reaction depletes local tryptophan and produces kynurenine, which together activate downstream GCN2 kinase signaling, inhibit mTORC1, and induce T-cell anergy. Kynurenine also acts as an endogenous ligand for the aryl hydrocarbon receptor (AhR), promoting regulatory T cell (Treg) differentiation and reinforcing immune suppression. IDO1 expression is strongly induced by IFN-?? via the JAK-STAT1 axis, and its activity is influenced by cofactors such as heme and interacting partners including SHP-1 and SHP-2. This network positions IDO1 at a critical junction between inflammatory signals and adaptive immune tolerance.
In the context of HT29 colorectal adenocarcinoma, IDO1-mediated tryptophan depletion and kynurenine production contribute to an immunosuppressive tumor microenvironment, facilitating immune escape and potentially limiting the efficacy of checkpoint inhibitors. Knocking out IDO1 in this intestinal epithelial model allows researchers to directly assess how loss of this enzyme alters local metabolic conditions, T-cell function, and Treg dynamics. The model therefore provides a physiologically relevant platform to study the contribution of IDO1 to colorectal cancer immune evasion and to evaluate combination therapies that target IDO1 alongside other immune-modulating agents.
Typical research applications include investigating IDO1-driven immune tolerance in colorectal cancer, dissecting synergy between IDO1 inhibition and checkpoint blockade, and modeling tumor microenvironment modulation. The polyclonal knockout cells enable functional assays such as T-cell suppression co-cultures, flow cytometric analysis of Treg markers, and transcriptomic profiling by RNA-seq. Barrier integrity studies via TEER measurements can also be performed to explore IDO1??s role in epithelial homeostasis. This knockout cell population offers a robust tool for mechanistic studies and drug discovery efforts aimed at restoring anti-tumor immunity. For further details, please contact Ascent Research.
